Moffitt Cancer Center launches AccelerOnc Studio
It's the first venture studio in the U.S. solely dedicated to oncology innovation.
Moffitt Cancer Center, a national leader in cancer research and treatment, has announced the launch of AccelerOnc Studio, the first venture studio in the U.S. solely dedicated to oncology innovation. The initiative aims to translate clinical, scientific, and technological expertise within health systems, beginning with Moffitt, into scalable solutions that improve outcomes for cancer patients worldwide.
AccelerOnc Studio will focus on identifying unmet clinical needs and commercializing intellectual property developed within health systems and cancer centers, starting with Moffitt’s own. By fostering early stage ventures rooted in real-world insights from frontline care and research, AccelerOnc is positioned to radically accelerate the path from innovation to impact in oncology.
“The launch of AccelerOnc Studio is a significant step in our mission to contribute bold breakthroughs in cancer research and care,” said Patrick Hwu, M.D., President and Chief Executive Officer of Moffitt. “This venture studio strengthens our ability to bring Moffitt’s expertise and innovations to cancer patients around the world and supports our strategy to lead in a new era where digital technologies and artificial intelligence are transforming how we understand and treat cancer.”
AccelerOnc will initially incubate companies based on Moffitt’s pipeline of ideas and intellectual property, then expand to include partners across the broader oncology ecosystem. The studio’s focus will span diagnostics, therapeutics, digital health, artificial intelligence, and data-driven platforms, all aimed at advancing cancer care.
Like what you've read?
Forward to a friend!